약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

Characteristics of the included studies

Author Country Intervention Study design Perspective Time horizon Discount rate Outcome
Chau et al. (2017)9) Netherlands Antiplatelet (Aspirin); PPI Cost-Utility Healthcare payer 5 years Cost (4%); Utility (1.5%) Cost
QALY
ICER
De Groot et al. (2013)10) Netherlands Antiplatelet (Aspirin 81 mg); PPI (omeprazole 20 mg/d) Cost-Utility Third party payer Lifetime 3% QALY
ICER
ACS
Earnshaw et al. (2011)11) United States of America Antiplatelet (Aspirin 81 mg); PPI (omeprazole 20 mg/d) Cost-Utility Third party payer 5-, 10 years, lifetime 3% Number of myocardial infarctions
Strokes
GI bleeding events
Cost
QALY
Life year
ICER
Saini et al. (2011)14) United States of America Antiplatelet (Aspirin); PPI Cost-Effectiveness Long-term payer Lifetime 3% GI bleeding events
Recurrent myocardial infarction and associated mortality
Aspirin Adherence
Cost
Life year
ICER
Saini et al. (2008)13) United States of America Antiplatelet (Aspirin); PPI Cost-Effectiveness Long-term payer Lifetime 3% UGIB & related death
Life year
ICER
Takabayashi et al. (2015)12) Japan Antiplatelet (Aspirin); PPI (Lansoprazole 30 mg or 15 mg) Cost-Effectiveness Healthcare payer 30 years 2% Duration of no therapy
Life year
ICER

ACS, acute coronary syndrome; GI, gastrointestinal bleeding; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; UGIB, upper gastrointestinal bleeding

Yakhak Hoeji 2022;66:292-301 https://doi.org/10.17480/psk.2022.66.5.292
© 2022 Yakhak Hoeji